;PMID: 10510729
;source_file_1212.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:44..178] = [t:44..178]
;2)section:[e:182..242] = [t:182..242]
;3)section:[e:246..351] = [t:246..351]
;4)sentence:[e:355..475] = [t:355..475]
;5)sentence:[e:476..683] = [t:476..683]
;6)sentence:[e:684..804] = [t:684..804]
;7)sentence:[e:805..938] = [t:805..938]
;8)sentence:[e:939..1178] = [t:939..1178]
;9)sentence:[e:1179..1382] = [t:1179..1382]
;10)sentence:[e:1383..1459] = [t:1383..1459]
;11)sentence:[e:1460..1633] = [t:1460..1633]
;12)sentence:[e:1634..1774] = [t:1634..1774]
;13)section:[e:1778..1823] = [t:1778..1823]

;section 0 Span:0..39
;Clin Chem Lab Med  1999 Jul;37(7):723-7
(SEC
  (FRAG (NNP:[0..4] Clin) (NNP:[5..9] Chem) (NNP:[10..13] Lab)
        (NNP:[14..17] Med) (CD:[19..23] 1999) (.:[24..31] Jul;37-LRB-)
        (CD:[31..33] 7-RRB-) (CD:[33..37] :723) (HYPH:[37..38] -)
        (CD:[38..39] 7)))

;sentence 1 Span:44..178
;A relationship between K-ras gene mutations and some clinical and histologic 
;variables in patients with primary colorectal carcinoma.
;[67..72]:gene-rna:"K-ras"
;[149..177]:malignancy:"primary colorectal carcinoma"
(SENT
  (NP-HLN
    (NP (DT:[44..45] A) (NN:[46..58] relationship))
    (PP (IN:[59..66] between)
      (NP
        (NP (NN:[67..72] K-ras) (NN:[73..77] gene) (NNS:[78..87] mutations))
        (CC:[88..91] and)
        (NP
          (NP (DT:[92..96] some)
            (ADJP (JJ:[97..105] clinical) (CC:[106..109] and)
                  (JJ:[110..120] histologic))
            (NNS:[122..131] variables))
          (PP (IN:[132..134] in)
            (NP
              (NP (NNS:[135..143] patients))
              (PP (IN:[144..148] with)
                (NP (JJ:[149..156] primary) (JJ:[157..167] colorectal)
                    (NN:[168..177] carcinoma))))))))
    (.:[177..178] .)))

;section 2 Span:182..242
;Beranek M, Bures J, Palicka V, Jandik P, Langr F, Nejedla E.
(SEC
  (FRAG (NNP:[182..189] Beranek) (NNP:[190..192] M,) (NNP:[193..198] Bures)
        (NNP:[199..201] J,) (NNP:[202..209] Palicka) (NNP:[210..211] V)
        (,:[211..212] ,) (NNP:[213..219] Jandik) (NNP:[220..221] P)
        (,:[221..222] ,) (NNP:[223..228] Langr) (NNP:[229..230] F)
        (,:[230..231] ,) (NNP:[232..239] Nejedla) (NNP:[240..242] E.)))

;section 3 Span:246..351
;Institute of Clinical Biochemistry and Diagnostics, University Hospital,
;Hradec  Kralove, Czech Republic.
(SEC
  (FRAG (NNP:[246..255] Institute) (IN:[256..258] of) (NNP:[259..267] Clinical)
        (NNP:[268..280] Biochemistry) (CC:[281..284] and)
        (NNP:[285..296] Diagnostics) (,:[296..297] ,)
        (NNP:[298..308] University) (NNP:[309..317] Hospital) (,:[317..318] ,)
        (NNP:[319..325] Hradec) (NNP:[327..334] Kralove) (,:[334..335] ,)
        (NNP:[336..341] Czech) (NNP:[342..350] Republic) (.:[350..351] .)))

;sentence 4 Span:355..475
;Mutations in the Kirsten ras 2 (K-ras) gene were described as early events in
; the process of colorectal carcinogenesis.
;[372..385]:gene-rna:"Kirsten ras 2"
;[387..392]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[355..364] Mutations))
      (PP (IN:[365..367] in)
        (NP (DT:[368..371] the)
          (NML
            (NML (NNP:[372..379] Kirsten) (NN:[380..383] ras) (CD:[384..385] 2))
            (NML (-LRB-:[386..387] -LRB-) (NN:[387..392] K-ras)
                 (-RRB-:[392..393] -RRB-)))
          (NN:[394..398] gene))))
    (VP (VBD:[399..403] were)
      (VP (VBN:[404..413] described)
        (NP-1 (-NONE-:[413..413] *))
        (PP (IN:[414..416] as)
          (NP
            (NP (JJ:[417..422] early) (NNS:[423..429] events))
            (PP (IN:[430..432] in)
              (NP
                (NP (DT:[434..437] the) (NN:[438..445] process))
                (PP (IN:[446..448] of)
                  (NP (JJ:[449..459] colorectal) (NN:[460..474] carcinogenesis)))))))))
    (.:[474..475] .)))

;sentence 5 Span:476..683
;The aim of this study was to find a  possible relationship between the
;presence of K-ras mutation in samples of  primary colorectal carcinomas and
;the clinico-pathological data of the  investigated patients.
;[559..564]:gene-rna:"K-ras"
;[589..618]:malignancy:"primary colorectal carcinomas"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[476..479] The) (NN:[480..483] aim))
      (PP (IN:[484..486] of)
        (NP (DT:[487..491] this) (NN:[492..497] study))))
    (VP (VBD:[498..501] was)
      (S-PRD
        (NP-SBJ (-NONE-:[501..501] *))
        (VP (TO:[502..504] to)
          (VP (VB:[505..509] find)
            (NP
              (NP (DT:[510..511] a) (JJ:[513..521] possible)
                  (NN:[522..534] relationship))
              (PP (IN:[535..542] between)
                (NP
                  (NP
                    (NP (DT:[543..546] the) (NN:[547..555] presence))
                    (PP (IN:[556..558] of)
                      (NP (NN:[559..564] K-ras) (NN:[565..573] mutation)))
                    (PP-LOC (IN:[574..576] in)
                      (NP
                        (NP (NNS:[577..584] samples))
                        (PP (IN:[585..587] of)
                          (NP (JJ:[589..596] primary) (JJ:[597..607] colorectal)
                              (NNS:[608..618] carcinomas))))))
                  (CC:[619..622] and)
                  (NP
                    (NP (DT:[623..626] the)
                      (ADJP (AFX:[627..634] clinico) (HYPH:[634..635] -)
                            (JJ:[635..647] pathological))
                      (NNS:[648..652] data))
                    (PP (IN:[653..655] of)
                      (NP (DT:[656..659] the) (VBN:[661..673] investigated)
                          (NNS:[674..682] patients)))))))))))
    (.:[682..683] .)))

;sentence 6 Span:684..804
;Mutation in codon 12 of the K-ras gene was determined in  18 of 53 colorectal
;carcinomas (34%) in our group of patients.
;[696..704]:variation-location:"codon 12"
;[712..717]:gene-rna:"K-ras"
;[751..772]:malignancy:"colorectal carcinomas"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[684..692] Mutation))
      (PP-LOC (IN:[693..695] in)
        (NP
          (NP (NN:[696..701] codon) (CD:[702..704] 12))
          (PP (IN:[705..707] of)
            (NP (DT:[708..711] the) (NN:[712..717] K-ras) (NN:[718..722] gene))))))
    (VP (VBD:[723..726] was)
      (VP (VBN:[727..737] determined)
        (NP-1 (-NONE-:[737..737] *))
        (PP (IN:[738..740] in)
          (NP
            (NP (CD:[742..744] 18))
            (PP (IN:[745..747] of)
              (NP (CD:[748..750] 53)
                 (JJ:[751..761] colorectal) (NNS:[762..772] carcinomas)))
            (PRN (-LRB-:[773..774] -LRB-)
              (NP (CD:[774..776] 34) (NN:[776..777] %))
              (-RRB-:[777..778] -RRB-))))
        (PP (IN:[779..781] in)
          (NP
            (NP (PRP$:[782..785] our) (NN:[786..791] group))
            (PP (IN:[792..794] of)
              (NP (NNS:[795..803] patients)))))))
    (.:[803..804] .)))

;sentence 7 Span:805..938
;The presence of  K-ras gene mutations was not related to gender, age of
;subject at diagnosis,  staging or cancer location (p > 0.05).
;[822..827]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[805..808] The) (NN:[809..817] presence))
      (PP (IN:[818..820] of)
        (NP (NN:[822..827] K-ras) (NN:[828..832] gene)
            (NNS:[833..842] mutations))))
    (VP (VBD:[843..846] was) (RB:[847..850] not)
      (VP (JJ:[851..858] related)
        (NP-1 (-NONE-:[858..858] *))
        (PP-CLR (TO:[859..861] to)
          (NP
            (NP (NN:[862..868] gender))
            (,:[868..869] ,)
            (NP
              (NP (NN:[870..873] age))
              (PP (IN:[874..876] of)
                (NP (NN:[877..884] subject)))
              (PP-TMP (IN:[885..887] at)
                (NP (NN:[888..897] diagnosis))))
            (,:[897..898] ,)
            (NP (NN:[900..907] staging))
            (CC:[908..910] or)
            (NP (NN:[911..917] cancer) (NN:[918..926] location)
              (PRN (-LRB-:[927..928] -LRB-)
                (S
                  (NP-SBJ (NN:[928..929] p))
                  (VP (SYM:[930..931] >)
                    (NP (CD:[932..936] 0.05))))
                (-RRB-:[936..937] -RRB-)))))))
    (.:[937..938] .)))

;sentence 8 Span:939..1178
;Sixteen of the 42 (38%) moderately  differentiated carcinomas, and two of the
;eight (25%) well differentiated  carcinomas contained K-ras mutation in codon
;12, but none of the three poorly  differentiated carcinomas contained the
;mutation.
;[963..1000]:malignancy:"moderately  differentiated carcinomas"
;[1029..1060]:malignancy:"well differentiated  carcinomas"
;[1071..1076]:gene-rna:"K-ras"
;[1089..1097]:variation-location:"codon 12"
;[1121..1154]:malignancy:"poorly  differentiated carcinomas"
;[1169..1177]:variation-event:"mutation"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (CD:[939..946] Sixteen))
        (PP (IN:[947..949] of)
          (NP (DT:[950..953] the) (CD:[954..956] 42)
            (PRN (-LRB-:[957..958] -LRB-)
              (NP (CD:[958..960] 38) (NN:[960..961] %))
              (-RRB-:[961..962] -RRB-))
            
            (ADJP (RB:[963..973] moderately) (VBN:[975..989] differentiated))
            (NNS:[990..1000] carcinomas))))
      (,:[1000..1001] ,) (CC:[1002..1005] and)
      (NP
        (NP (CD:[1006..1009] two))
        (PP (IN:[1010..1012] of)
          (NP (DT:[1013..1016] the) (CD:[1017..1022] eight)
            (PRN (-LRB-:[1023..1024] -LRB-)
              (NP (CD:[1024..1026] 25) (NN:[1026..1027] %))
              (-RRB-:[1027..1028] -RRB-))
            
            (ADJP (RB:[1029..1033] well) (VBN:[1034..1048] differentiated))
            (NNS:[1050..1060] carcinomas)))))
    (VP (VBD:[1061..1070] contained)
      (NP
        (NP (NN:[1071..1076] K-ras) (NN:[1077..1085] mutation))
        (PP-LOC (IN:[1086..1088] in)
          (NP (NN:[1089..1094] codon) (CD:[1095..1097] 12))))))
  (,:[1097..1098] ,) (CC:[1099..1102] but)
  (S
    (NP-SBJ
      (NP (NN:[1103..1107] none))
      (PP (IN:[1108..1110] of)
        (NP (DT:[1111..1114] the) (CD:[1115..1120] three)
          
          (ADJP (RB:[1121..1127] poorly) (VBN:[1129..1143] differentiated))
          (NNS:[1144..1154] carcinomas))))
    (VP (VBD:[1155..1164] contained)
      (NP (DT:[1165..1168] the) (NN:[1169..1177] mutation))))
  (.:[1177..1178] .))
;ERROR_Sentence has multiple children (TB Error):[939..1178]::S:,:CC:S:.:

;sentence 9 Span:1179..1382
;Moderately differentiated  tumours contained an aspartate code GAT (in eight
;cases), a valine code GTT (in  six cases), an alanine code GCT (in one case)
;and a serine code AGT (in one  case) in codon 12.
;[1179..1213]:malignancy:"Moderately differentiated  tumours"
;[1227..1236]:variation-state-generic:"aspartate"
;[1242..1245]:variation-state-generic:"GAT"
;[1266..1272]:variation-state-generic:"valine"
;[1278..1281]:variation-state-generic:"GTT"
;[1302..1309]:variation-state-generic:"alanine"
;[1315..1318]:variation-state-generic:"GCT"
;[1339..1345]:variation-state-generic:"serine"
;[1351..1354]:variation-state-generic:"AGT"
;[1373..1381]:variation-location:"codon 12"
(SENT
  (S
    (NP-SBJ
      (ADJP (RB:[1179..1189] Moderately) (VBN:[1190..1204] differentiated))
      (NNS:[1206..1213] tumours))
    (VP (VBD:[1214..1223] contained)
      (NP
        (NP (DT:[1224..1226] an)
          (NML
            (NML (NN:[1227..1236] aspartate) (NN:[1237..1241] code))
            (NML (NN:[1242..1245] GAT)))
          (PRN (-LRB-:[1246..1247] -LRB-)
            (PP (IN:[1247..1249] in)
              (NP (CD:[1250..1255] eight) (NNS:[1256..1261] cases)))
            (-RRB-:[1261..1262] -RRB-)))
        (,:[1262..1263] ,)
        (NP (DT:[1264..1265] a)
          (NML
            (NML (NN:[1266..1272] valine) (NN:[1273..1277] code))
            (NML (NN:[1278..1281] GTT)))
          (PRN (-LRB-:[1282..1283] -LRB-)
            (PP (IN:[1283..1285] in)
              (NP (CD:[1287..1290] six) (NNS:[1291..1296] cases)))
            (-RRB-:[1296..1297] -RRB-)))
        (,:[1297..1298] ,)
        (NP (DT:[1299..1301] an)
          (NML
            (NML (NN:[1302..1309] alanine) (NN:[1310..1314] code))
            (NML (NN:[1315..1318] GCT)))
          (PRN (-LRB-:[1319..1320] -LRB-)
            (PP (IN:[1320..1322] in)
              (NP (CD:[1323..1326] one) (NN:[1327..1331] case)))
            (-RRB-:[1331..1332] -RRB-)))
        (CC:[1333..1336] and)
        (NP (DT:[1337..1338] a)
          (NML
            (NML (NN:[1339..1345] serine) (NN:[1346..1350] code))
            (NML (NN:[1351..1354] AGT)))
          (PRN (-LRB-:[1355..1356] -LRB-)
            (PP (IN:[1356..1358] in)
              (NP (CD:[1359..1362] one) (NN:[1364..1368] case)))
            (-RRB-:[1368..1369] -RRB-))))
      (PP (IN:[1370..1372] in)
        (NP (NN:[1373..1378] codon) (CD:[1379..1381] 12))))
    (.:[1381..1382] .)))

;sentence 10 Span:1383..1459
;Well differentiated tumours contained only the valine code  GTT (two cases).
;[1383..1410]:malignancy:"Well differentiated tumours"
;[1430..1436]:variation-state-generic:"valine"
;[1443..1446]:variation-state-generic:"GTT"
(SENT
  (S
    (NP-SBJ
      (ADJP (RB:[1383..1387] Well) (VBN:[1388..1402] differentiated))
      (NNS:[1403..1410] tumours))
    (VP (VBD:[1411..1420] contained)
      (NP (RB:[1421..1425] only)
        (NML (DT:[1426..1429] the) (NN:[1430..1436] valine)
             (NN:[1437..1441] code))
        (NML (NN:[1443..1446] GTT))
        (PRN (-LRB-:[1447..1448] -LRB-)
          (NP (CD:[1448..1451] two) (NNS:[1452..1457] cases))
          (-RRB-:[1457..1458] -RRB-))))
    (.:[1458..1459] .)))

;sentence 11 Span:1460..1633
;Our results show that the frequency of mutations in the K-ras  gene in
;carcinomas in Central Europe is not different from the frequencies found  in
;other parts of the world.
;[1516..1521]:gene-rna:"K-ras"
;[1531..1541]:malignancy:"carcinomas"
(SENT
  (S
    (NP-SBJ (PRP$:[1460..1463] Our) (NNS:[1464..1471] results))
    (VP (VBP:[1472..1476] show)
      (SBAR (IN:[1477..1481] that)
        (S
          (NP-SBJ
            (NP (DT:[1482..1485] the) (NN:[1486..1495] frequency))
            (PP (IN:[1496..1498] of)
              (NP
                (NP (NNS:[1499..1508] mutations))
                (PP (IN:[1509..1511] in)
                  (NP (DT:[1512..1515] the) (NN:[1516..1521] K-ras)
                      (NN:[1523..1527] gene)))))
            (PP-LOC (IN:[1528..1530] in)
              (NP (NNS:[1531..1541] carcinomas)))
            (PP-LOC (IN:[1542..1544] in)
              (NP (JJ:[1545..1552] Central) (NNP:[1553..1559] Europe))))
          (VP (VBZ:[1560..1562] is)
            (ADJP-PRD (RB:[1563..1566] not) (JJ:[1567..1576] different)
              (PP (IN:[1577..1581] from)
                (NP
                  (NP (DT:[1582..1585] the) (NNS:[1586..1597] frequencies))
                  (VP (VBN:[1598..1603] found)
                    (NP (-NONE-:[1603..1603] *))
                    (PP (IN:[1605..1607] in)
                      (NP
                        (NP (JJ:[1608..1613] other) (NNS:[1614..1619] parts))
                        (PP (IN:[1620..1622] of)
                          (NP (DT:[1623..1626] the) (NN:[1627..1632] world)))))))))))))
    (.:[1632..1633] .)))

;sentence 12 Span:1634..1774
;The homogeneous incidence of K-ras mutation does  not seem to be related to
;ethnic factors, dietary habits, or the composition of  the diet.
;[1663..1668]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1634..1637] The) (JJ:[1638..1649] homogeneous)
          (NN:[1650..1659] incidence))
      (PP (IN:[1660..1662] of)
        (NP (NN:[1663..1668] K-ras) (NN:[1669..1677] mutation))))
    (VP (VBZ:[1678..1682] does) (RB:[1684..1687] not)
      (VP (VB:[1688..1692] seem)
        (S
          (NP-SBJ-2 (-NONE-:[1692..1692] *))
          (VP (TO:[1693..1695] to)
            (VP (VB:[1696..1698] be)
              (VP (JJ:[1699..1706] related)
                (NP-2 (-NONE-:[1706..1706] *))
                (PP-CLR (TO:[1707..1709] to)
                  (NP
                    (NP (JJ:[1710..1716] ethnic) (NNS:[1717..1724] factors))
                    (,:[1724..1725] ,)
                    (NP (JJ:[1726..1733] dietary) (NNS:[1734..1740] habits))
                    (,:[1740..1741] ,) (CC:[1742..1744] or)
                    (NP
                      (NP (DT:[1745..1748] the) (NN:[1749..1760] composition))
                      (PP (IN:[1761..1763] of)
                        (NP (DT:[1765..1768] the) (NN:[1769..1773] diet))))))))))))
    (.:[1773..1774] .)))

;section 13 Span:1778..1823
;PMID: 10510729 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1778..1782] PMID) (::[1782..1783] :) (CD:[1784..1792] 10510729)
        (IN:[1793..1794] -LSB-) (NNP:[1794..1800] PubMed) (HYPH:[1801..1802] -)
        (JJ:[1803..1810] indexed) (IN:[1811..1814] for)
        (NNP:[1815..1823] MEDLINE-RSB-)))
